Bayer AG · XETR:BAYN
Bayer — 40th Annual J.P. Morgan Healthcare Conference 2022
12 slides from Bayer's conference presentation, Jan 10, 2022
Slide 1: J.P. Morgan Healthcare Conference
40th Annual J.P. Morgan Healthcare Conference January 10-13, 2022 /////////// Stefan Oelrich Member of the Board of Management of Bayer AG President of the Pharmaceuticals Division 1 /// JP Morgan Healthcare Conference /// January 10-13, 2022
Slide 2: Cautionary statements regarding forward-looking information
Cautionary statements regarding forward-looking information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the ac
Slide 3: Bayer Pharma is delivering on strategic growth agenda
Bayer Pharma is delivering on strategic growth agenda 2018 - 2021 2021+ Capitalize on full Strengthened patent situation in EU commercial potential Life Cycle management Deliver on new >1bn sales Elinzanetant blockbusters ARASENS data FXI(a) portfolio Strengthen New leadership team innovation engine
Slide 4: On track to deliver on raised top-line guidance, while keeping attractive margin
On track to deliver on raised top-line guidance, while keeping attractive margin amid continued investments in growth Year-on-year sales growth (cpa) +7% Top-line guidance for FY 2021 raised Q1: +0% ~6% in August reflecting continued positive momentum Strong sales recovery Q2 onwards ~4% after 2020
Slide 5: Capturing the full commercial potential of market leading therapies
Capturing the full commercial potential of market leading therapies +7.7% +20.6% yoy in 9M 2021 yoy in 9M 2021 New indications & label updates in 2021 2 Phase III studies with high-dose formulation (initiated 2020) Pediatric VTE: approved in EU, Japan, Canada PHOTON (DME) (EINSTEIN Jr) and the US (E
Slide 6: Nubeqa to become foundational drug across patient spectrum in prostate cancer
Nubeqa to become foundational drug across patient spectrum in prostate cancer – further data to be released in Feb 2022 Highly differentiated ‘Survival without compromise’, giving NUBEQA the potential Strong efficacy tolerability profile to be used across the entire spectrum of PC nmCRPC mHSPC Adjuv
Slide 7: Kerendia a game changer for CKD and type 2 diabetes patients
Kerendia a game changer for CKD and type 2 diabetes patients Next milestone in renal disease treatment, continuing our RAAS-centric treatment history Largest clinical program Successful launch trajectory Entresto with unparalleled data1 2020 Weekly TRx (US) Novel MOA intensifies 3.000 RAAS inhibitio
Slide 8: Novel drug candidates in Women's Health and Cardiovascular Diseases
Novel drug candidates in Women’s Health and Cardiovascular Diseases to drive mid-term growth Transformative approach for Next class of anticoagulation drug menopause syndromes candidates with disruptive potential Elinzanetant (2025) World leading factor XI program (2026) Addressing menopause syndrom
Slide 9: Advancing leading CGT platform with strong clinical pipeline
Advancing leading CGT platform with strong clinical pipeline Example: Two-pronged approach to deliver transformative therapies to treat Parkinson’s Diverse tech platforms and capabilities AAV platform (AskBio and Successful administration Bayer established) of first dose of DA011 to a BlueRock´s iPS
Slide 10: Our innovation engine is delivering
Our innovation engine is delivering 2 Committed and experienced External new leadership team Innovation 1 3 Advancing leading cell and Internal Platform gene therapy business Innovation Companies World leading science added 1 2 3 through new platforms Global R&D Collaborations, CGT SMOL organization
Slide 11: Bayer Pharma: Shaping the foundation for long-term growth
Bayer Pharma: Shaping the foundation for long-term growth Fully capturing Building new Innovation engine is Maintain attractive commercial value of blockbusters with delivering across all margins amid market leading therapeutic stages of clinical investments in therapies breakthrough development gro
Slide 12: J.P. Morgan Healthcare Conference
40th Annual J.P. Morgan Healthcare Conference January 10-13, 2022 /////////// Stefan Oelrich Member of the Board of Management of Bayer AG President of the Pharmaceuticals Division 12 /// JP Morgan Healthcare Conference /// January 10-13, 2022
Bayer — 40th Annual J.P. Morgan Healthcare Conference 2022 on 6ix